Cognitive Decline
Cognitive Decline screening by GIA®, powered by digitalhumanOS™, uses Voice AI, Computer Vision, and Speech Biomarkers to detect cognitive decline through a single patient conversation. Screening performance: AUC 0.890. Screening takes 40 seconds with results in under 2 minutes.
Subtle cognitive changes often go unnoticed, impacting communication and hindering rehabilitation.
Early detection of cognitive decline allows for tailored care plans in post-acute care. By understanding patient cognitive abilities, we can optimize therapy and improve outcomes.
Key Facts
- Screening Time
- 40 seconds
- Results
- under 2 minutes
- Modalities
- Voice + Vision + Speech
- Validation
- Peer-Reviewed (19 studies)
- Status
- Live
This content is intended for informational purposes and does not constitute medical advice. Editorially reviewed by David Kaiser, CEO of Scienza Health, for accuracy in post-acute care operations.
About Cognitive Decline screening.
How does the system detect cognitive decline?
The system analyzes speech patterns, vocal characteristics, and cognitive tasks to assess cognitive function.
How can this information be used to improve patient care?
Identifying cognitive decline allows for adjustments to therapy techniques, communication strategies, and environmental modifications.
What is the accuracy rate for detecting cognitive decline?
The model achieves an accuracy rate of 70.8%.
The science behind Cognitive Decline screening.
Kiyoshige et al. (2025) published in The Lancet Regional Health — Western Pacific report that the inclusion of voice biomarkers significantly improved cognitive-impairment detection AUC from 0.80 (0.76–0.84) to 0.88 (0.84–0.91), and from 0.78 (0.73–0.82) to 0.89 (0.86–0.92), in a cross-sectional study of 1,461 community-dwelling Japanese adults of which 526 (36.0%) had cognitive impairment. DOI: 10.1016/j.lanwpc.2025.101598.
Developing and testing AI-based voice biomarker models to detect cognitive impairment among community dwelling adults: a cross-sectional study in Japan — The Lancet Regional Health — Western Pacific (2025-06) · Japan's National Cerebral and Cardiovascular Center (NCVC)Peer-reviewed research demonstrates that spontaneous conversational speech contains detectable biomarkers for Mild Cognitive Impairment — enabling screening without scripted prompts or clinical interviews.
Detecting Mild Cognitive Impairment using Vocal Biomarkers from Spontaneous Speech (2024-09)Clinical research establishes voice analysis as a validated approach to early MCI detection — addressing a condition missed by primary care physicians in 92% of cases.
Mild Cognitive Impairment (MCI) Detection via Voice Analysis (2023-01)A real-world health innovation study demonstrates that voice biomarker technology provides objective data for assessing cognitive wellness — improving patient outcomes in community health settings.
Wyoming Health Innovation Living Lab Case Study (2024-01)A 2011 meta-analysis of primary-care physician accuracy (Mitchell, Meader, Pentzek, Acta Psychiatrica Scandinavica) found GPs recognized 44.7% of MCI cases by clinical judgment and documented the recognition in medical records only 10.9% of the time — about half of MCI cases were missed and the majority of recognized cases went unrecorded.
Clinical recognition of dementia and cognitive impairment in primary care: a meta-analysis of physician accuracy — Acta Psychiatrica Scandinavica (2011-09)DOI: 10.1111/j.1600-0447.2011.01730.x →Mattke et al. observational analysis of the full Medicare population 2015–2019 (Alzheimer's Research & Therapy 2023) found that 7.4 of 8 million (92%) expected MCI cases remained undiagnosed, with substantial racial disparities in dementia detection.
Expected and diagnosed rates of mild cognitive impairment and dementia in the U.S. Medicare population: observational analysis — Alzheimer's Research & Therapy (2023-07)DOI: 10.1186/s13195-023-01272-z →Manly et al. (JAMA Neurology 2022) used the 2016 HRS Harmonized Cognitive Assessment Protocol to estimate that 22% of US adults age 65 and older have mild cognitive impairment, providing a nationally representative prevalence baseline.
Estimating the Prevalence of Dementia and Mild Cognitive Impairment in the US: The 2016 Health and Retirement Study Harmonized Cognitive Assessment Protocol Project — JAMA Neurology (2022-12)DOI: 10.1001/jamaneurol.2022.3543 →The Framingham Heart Study, analyzing over 4,000 voice recordings paired with MRI-derived brain data, found that vocal markers including jitter, articulation rate, and lexical diversity are significantly associated with structural changes in memory-related brain regions.
Framingham Heart Study — Voice and Brain Structure Correlation (2026-03) · NIH Bridge2AI-Voice Consortium, Boston University, Vanderbilt University Medical CenterPorter et al. (Journal of General Internal Medicine 2023) estimated that primary care physicians would need 26.7 hours per day to deliver all guideline-recommended preventive, chronic disease, and acute care to a representative 2,500-patient panel — quantifying the structural gap that drives systematic under-delivery of screening elements in primary care.
Revisiting the Time Needed to Provide Adult Primary Care — Journal of General Internal Medicine (2023-01)DOI: 10.1007/s11606-022-07707-x →AUC 0.890 for cognitive decline detection from natural conversation. Verified via confidential strategic clinical-validation partner; partner identity withheld per partnership agreement. Operator-confirmed 2026-05-20.
Strategic partner clinical-validation study (cognitive decline) (2026)View all peer-reviewed research. See how GIA® screens for Cognitive Decline across care settings.
The Operator's Guide to Multimodal Clinical AI
What administrators, DONs, and regional operators need to know before evaluating clinical AI platforms. Covers EHR integration, staffing impact, reimbursement codes, and deployment timelines.